Crossmark

Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)

Crossref DOI link: https://doi.org/10.1186/s13063-021-05541-w

Published Online: 2021-08-26

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yamada, Daisaku https://orcid.org/0000-0002-6702-3800
Kobayashi, Shogo

Takahashi, Hidenori

Akita, Hirofumi

Yamada, Terumasa

Asaoka, Tadafumi

Shimizu, Junzo

Takeda, Yutaka

Yokoyama, Shigekazu

Tsujie, Masanori

Tomokuni, Akira

Tanemura, Masahiro

Morimoto, Osakuni

Murakami, Masahiro

Kim, Yongkook

Nakahira, Shin

Hama, Naoki

Sugimoto, Keishi

Hashimoto, Kazuhiko

Doki, Yuichiro

Eguchi, Hidetoshi
License Information

Text and Data Mining valid from 2021-08-26

Version of Record valid from 2021-08-26
More Information

Article History

Received: 3 March 2021

Accepted: 13 August 2021

First Online: 26 August 2021

Declarations

:

: This study protocol was approved by the ethics committee of Osaka University Clinical Research Review Committee (No. CRB5180007, affiliation of the principal investigator) and other participating institutions.The present protocol is the fourth amendment.

: Not applicable.

: CSGO-HBP reports no competing interests.

Document is current

Any future updates will be listed below